Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

Key Points

• HC Wainwright raised Urogen Pharma’s Q3 2026 EPS estimate to a loss of $0.07 per share from a previous forecasted loss of $0.37, while maintaining a “Buy” rating and a $75 price target.
• Analyst sentiment is broadly positive, with Urogen carrying a “Moderate Buy” consensus rating and an average price target of $48.78; several firms recently raised their targets to between $50 and $60.
• Urogen’s latest quarterly results showed a $0.28 per-share loss, slightly missing estimates, but revenue of $72.46 million exceeded the $63.55 million consensus forecast. Shares opened at $46.96, near their 52-week high of $48.19.

Urogen Pharma (NASDAQ:URGN - Free Report) - Research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Urogen Pharma in a research note issued on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Urogen Pharma's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Urogen Pharma's Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.17 EPS and FY2027 earnings at $1.05 EPS.

URGN has been the subject of several other research reports. Oppenheimer increased their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. TD Cowen upped their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a research note on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Urogen Pharma in a report on Friday, July 17th. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a report on Monday, May 11th. They set a "buy" rating and a $43.00 price objective for the company. Finally, Guggenheim lifted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Urogen Pharma currently has an average rating of "Moderate Buy" and an average target price of $48.78.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock opened at $46.96 on Monday. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.72 and a beta of 1.57. The stock's 50-day simple moving average is $36.44 and its 200-day simple moving average is $27.18. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $48.19.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million.

Insider Activity

In other news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the sale, the insider directly owned 119,763 shares of the company's stock, valued at approximately $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,222 shares of company stock valued at $892,661 over the last quarter. Insiders own 4.80% of the company's stock.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Persistent Asset Partners Ltd bought a new stake in Urogen Pharma in the 2nd quarter worth approximately $66,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company's stock worth $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company's stock valued at $66,000 after acquiring an additional 3,125 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after purchasing an additional 5,571 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source